Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Harbin Pharmaceutical Group Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 4/6
Harbin Pharmaceutical Group has been growing earnings at an average annual rate of 49.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 8.3% per year. Harbin Pharmaceutical Group's return on equity is 10.7%, and it has net margins of 3.5%.
Anahtar bilgiler
49.5%
Kazanç büyüme oranı
49.6%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 10.9% |
| Gelir büyüme oranı | 8.3% |
| Özkaynak getirisi | 10.7% |
| Net Marj | 3.5% |
| Sonraki Kazanç Güncellemesi | 26 Oct 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Harbin Pharmaceutical Group Co., Ltd. (SHSE:600664) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25
Investors Aren't Buying Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Earnings
Jun 25We Think Harbin Pharmaceutical Group (SHSE:600664) Can Manage Its Debt With Ease
May 25Harbin Pharmaceutical Group's (SHSE:600664) Anemic Earnings Might Be Worse Than You Think
Apr 17Gelir ve Gider Dağılımı
Harbin Pharmaceutical Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 15,895 | 556 | 3,470 | 112 |
| 31 Mar 24 | 15,667 | 450 | 3,321 | 98 |
| 31 Dec 23 | 15,457 | 395 | 3,169 | 106 |
| 30 Sep 23 | 15,312 | 599 | 3,086 | 105 |
| 30 Jun 23 | 15,096 | 526 | 2,972 | 111 |
| 31 Mar 23 | 14,406 | 487 | 2,752 | 124 |
| 31 Dec 22 | 13,809 | 465 | 2,566 | 116 |
| 30 Sep 22 | 13,053 | 41 | 2,579 | 114 |
| 30 Jun 22 | 12,812 | 151 | 2,411 | 108 |
| 31 Mar 22 | 13,156 | 389 | 2,367 | 100 |
| 31 Dec 21 | 12,802 | 371 | 2,317 | 98 |
| 30 Sep 21 | 12,879 | -219 | 2,590 | 80 |
| 30 Jun 21 | 12,385 | -402 | 2,654 | 80 |
| 31 Mar 21 | 11,258 | -808 | 2,775 | 88 |
| 31 Dec 20 | 10,788 | -1,078 | 2,852 | 93 |
| 30 Sep 20 | 11,009 | -321 | 2,482 | 113 |
| 30 Jun 20 | 11,118 | -235 | 2,442 | 122 |
| 31 Mar 20 | 11,661 | 14 | 2,368 | 125 |
| 31 Dec 19 | 11,825 | 56 | 2,411 | 125 |
| 30 Sep 19 | 11,174 | 107 | 2,308 | 131 |
| 30 Jun 19 | 10,696 | -59 | 2,336 | 122 |
| 31 Mar 19 | 10,630 | 61 | 2,240 | 130 |
| 31 Dec 18 | 10,814 | 346 | 2,170 | 137 |
| 30 Sep 18 | 10,910 | 386 | 2,197 | 134 |
| 30 Jun 18 | 11,484 | 422 | 2,192 | 215 |
| 31 Mar 18 | 11,790 | 501 | 2,297 | 176 |
| 31 Dec 17 | 12,018 | 407 | 2,349 | 142 |
| 30 Sep 17 | 12,993 | 441 | 2,540 | 101 |
| 30 Jun 17 | 13,180 | 757 | 2,529 | 0 |
| 31 Mar 17 | 13,761 | 737 | 2,626 | 0 |
| 31 Dec 16 | 14,127 | 788 | 2,665 | 0 |
| 30 Sep 16 | 13,662 | 789 | 2,439 | 0 |
| 30 Jun 16 | 13,830 | 584 | 2,602 | 0 |
| 31 Mar 16 | 14,435 | 515 | 2,750 | 0 |
| 31 Dec 15 | 15,856 | 580 | 3,035 | 0 |
| 30 Sep 15 | 16,038 | 324 | 3,255 | 0 |
| 30 Jun 15 | 16,622 | 302 | 3,491 | 0 |
| 31 Mar 15 | 16,290 | 238 | 3,673 | 0 |
| 31 Dec 14 | 16,509 | 247 | 4,009 | 0 |
| 30 Sep 14 | 17,382 | 230 | 4,600 | 0 |
| 30 Jun 14 | 18,019 | 307 | 4,811 | 0 |
| 31 Mar 14 | 18,402 | 107 | 4,956 | 0 |
| 31 Dec 13 | 18,092 | 169 | 4,845 | 0 |
Kaliteli Kazançlar: 600664 has high quality earnings.
Büyüyen Kar Marjı: 600664's current net profit margins (3.5%) are higher than last year (3.5%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 600664 has become profitable over the past 5 years, growing earnings by 49.5% per year.
Büyüme Hızlandırma: 600664's earnings growth over the past year (5.7%) is below its 5-year average (49.5% per year).
Kazançlar vs. Sektör: 600664 earnings growth over the past year (5.7%) exceeded the Pharmaceuticals industry -0.6%.
Özkaynak Getirisi
Yüksek ROE: 600664's Return on Equity (10.7%) is considered low.